Skip to main content
. Author manuscript; available in PMC: 2020 Oct 2.
Published in final edited form as: ACS Nano. 2020 Jun 2;14(6):7200–7215. doi: 10.1021/acsnano.0c02207

Figure 6.

Figure 6.

Therapeutic efficacy following depletion of T cells or NK cells. Mouse survival (A) and tumor growth plots as measured from bioluminescence images (B), for mice treated with PRINT-CpG (20 μg), untreated (No Tx), depleted of CD8 T cells and treated with PRINT-CpG (20 μg), and depleted of NK cells and treated with PRINT-CpG (20 μg) (n = 5 mice per treatment group).